A.n.n.
@fireflyann
volunteer #CRCSM librarian #BRAF & #NRAS FB grps Stage 4 CRC Support & Colon Cancer Stars trials Stage 2/3 pts https://www.facebook.com/groups/369712783922671/
Started a BRAF Colorectal Cancer Public Library group on Facebook. So many significant trials, research findings, changes to NCCN guidelines, etc. in the last 2 years. Gathering high level research/interviews into 1 place seems wise and useful. #BRAFCRC facebook.com/groups/2084906…
Sharon Osbourne was in one of my favorite PSA's for colorectal cancer. Humorous and personal, honest and attention getting. From 2018. @AmericanCancer youtube.com/watch?v=M-eT1K…
Adagene announces positive FDA feedback on its clinical development plan for Muzastotug (ADG126) in MSS colorectal cancer following a productive Type B meeting. 🔗 Read more: investor.adagene.com/news-releases/…
Wow. I am updating my profile to 18 year survivor instead of 17 years. I am here to show that early age onset of colorectal cancer can be a long and incredible life. I stand proud as a research advocate to show that the patient voice is important and not to be disregarded.
Really impressed by the Resources from the @ClevelandClinic Center for Young-Onset Colorectal Cancer - for patients and their family members @DavidLiskaMD @smitha42 my.clevelandclinic.org/departments/di… @CancerInsider @FightCRC Colon Camp!
The 1st patient has been dosed in the Phase 1 clinical trial of MOMA-313, a novel, highly potent & selective oral POLq helicase inhibitor, & we've selected our 2nd development candidate, MOMA-341, an oral Werner helicase inhibitor. Read & learn more: businesswire.com/news/home/2024…
NCT06974110 open in TX & Australia #AACR25 preclinical research Direct measurement of TA repeat expansions significantly outperforms MSI-H status as a predictor of sensitivity to the novel WRN inhibitor MOMA-34 aacrjournals.org/.../85/8_Suppl… Poster on MT website momatx.com/wp-content/upl…
We're pleased to share that we’ve dosed the first patient in the Phase 1 trial of MOMA-341, a potent oral Werner helicase inhibitor discovered with our KNOMATIC™ platform, for advanced MSI-H/dMMR tumors. Read more: businesswire.com/news/home/2025…
💯 % agree “discontinuing trials for which participants have already volunteered and are undergoing treatment does an enormous disservice to patients.”
Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials
Implications of BRAF V600E in dMMR/MSI-H pts treated with ICIs. Prognostic impact of the BRAF V600E mutation in patients with MSI-high... sciencedirect.com/science/articl… @AACR @JCO_ASCO @ASCO @MayoCancerCare
Join me live tomorrow at 7pm ET on Zoom to hear from Dr. @kevinburns on #histotripsy for colorectal cancer liver mets—details on flyer. 💙 #crcsm #mCRC #livermets @histosonics @colontown @manjuggm @fireflyann
I was patient advocate voice on the @FightCRC webinar Research Updates from ASCO 2025 Six presentations discussed by Dr. @smitha42 two I/O trials for MSS Stage IV patients (XTX101, DSP-107) BREAKWATER CHECKMATE 8HW ATOMIC CHALLENGE #ASCO25 #CRCSM youtube.com/watch?v=f8FZQO…
📘Early-onset colorectal cancer @ASCO Educational Book 👉ascopubs.org/doi/10.1200/ED… #cancer #oncology #MedX @OncoAlert @realbowtiedoc
#TumorBoardTuesday 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer So to put this in context: 📢Join us Tuesday, 07-08-25 at 8PM ET as @DrShubhamPant & @DanielHaldarMD 🗣️Optimizing 1L Treatment Selection in mPDAC RT and bring others into the discussion‼️
Over the weekend at #ESMOGI25, our botensilimab/balstilimab investigational combo presented new MSS #colorectalcancer data, showing consistent results over extended follow-up. See the full presentation here: bit.ly/4lHjMxE #Immunotherapy #CancerResearch
Real-world data on the safety and eficacy of ENCO plus PANI in BRAF V600E mutated mCRC patients who experienced severe toxicity with CET. ORR, PFS and OS are comparable to those reported in the BEACON trial -> potential option in patients unable to continue CET. #ESMOGI2025
Closing the session is #DrMichaelOverman re: where are with re: immunotherapy in met #crcsm #colorectal #cancer. Excellent lecture re: future developments! @myESMO #cancer #cancerresearch @MDAndersonNews #ESMOGI2025 #ESMOAmbassadors
Great talk from Dr. M Overman @MDAndersonNews re: overview on the role of #immunotherapy in #colorectalcancer. Looking forward to this paper in press from @VanMorrisMD re: correlates from his phase 2 single arm study for BRAF refractory #CRCSM pts with IO. @myESMO #ESMOGI2025…
Phenomenal session by Dr Michael Overman of @MDAndersonNews The OG showed up! Also his session for MSI crc was a tour de force! To see all that has happened and that a better future is on the brink. Worldwide efforts paying off!
Great overview by @michael_overman of pMMR #CRC and efforts to modulate for immunotherapy response. Important to learn from negative studies, but also consider that responses might be different in earlier disease stages. #ESMOAmbassadors #ESMOGI25
Closing remarks at @myESMO #ESMOGI25 Patient perspective lecture by #Dice Many steps to improve 👉Early diagnosis- let’s be proactive 👀Early on-set 🤝Decision making beyond signing informed consent 🫂Communication - what, how, when matters #ESMOAmbassadors
#ESMOGI25 was an incredible experience — truly honored to present results from the PARERE study by @FoundationGono in the Proffered Session
Happening now: Dr. Rene Adam providing an update on metastatic #colorectal #cancer to the liver regarding #Transmet study and #livertransplant. @myESMO #ESMOGI25 #ESMOGI2025 #Cancer #CancerResearch